Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) traded at $13.86 at last check on Friday, Oct 16, making a downturn move of -9.35% on its previous day’s price.
Looking at the stock we see that its previous close was $15.29 and the beta (5Y monthly) reads 0.75 with the day’s price range being $13.79 – 15.45. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, BCLI has a high of $17.95 and a low of $3.58. The company’s stock has gained about -5.2% over that past 30 days.
Brainstorm has a market cap of $441.44 Million and is expected to release its quarterly earnings report on October 15, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the BCLI stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.26, with the EPS growth for the year declined at -$1.15 for 2020 and -$0.7 for next year. These figures represent 0.08% and at -0.39% growth in EPS for the two years respectively.
On the other hand, looking at the outlook for the BCLI stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 2 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Brainstorm Cell Therapeutics Inc. (BCLI) stock as a Hold, while 2 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the BCLI stock currently stands at 0, and the current price level is -13% off its SMA20 and -2.56% from its 50-day simple moving average. The RSI (14) is pointing at 39.8 while the volatility over the past week is 9.06% and drops to 6.97% over the past one month. The beta value is 0.75, while the average true range (ATR) is currently pointing at 1.07. The average price target for the stock over the next 12 months is $22.5, with the estimates having a low of $20 and a high of $25. These price ends are 44.3% and +80.38% off the current price level respectively, although investors could be excited at the prospect of a +62.34% if the BCLI share price touches on the median price of $22.5.
Let’s briefly compare Brainstorm (BCLI) stock to its peers. We find that today’s price change of -9.35% and +255.38% over the past 12 months for BCLI competes that of Amgen Inc (AMGN), which has seen its stock price rise 0.3% in the latest trading session and is +15.8% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 1.36% today, and is +16.83% up over the past year, while Gilead Sciences Inc (GILD) is also down -9.35% yet its price remains in the green at 255.38% over the same period. Amgen has a P/E ratio of 19.26 compared to Brainstorm’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.01% and 0.39%, respectively, in early deals.
Coming back to Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), we note that the average 3-month trading volume was 502.19 Million, while that of the preceding 10-day period stands at 480.96 Million. Current shares outstanding are 31.53 Million.
According to data from Thomson Reuters, insiders hold 22.34% of the company’s shares while institutions hold 8.79%. The data shows that short shares as of September 29, 2020, stood at 4.53 Million at a short ratio of 12.71. This represents a 14.38% Short interest in Shares outstanding on September 29, 2020. Shares short rose in September from the previous month at 3.89 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +223.83% up in year-to-date price movement.